PUBLIC COMPANY
savePriovant Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA green lights Priovant drug for rare skin diseaseLisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.biopharma_dive · 1mo ago
- Priovant nabs first FDA approval for targeted tablet in dermatomyositisLisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with the rare autoimmune disease, setting up the drug for blockbuster status…biospace · 1mo ago
- FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in AdultsThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.fda_press · 1mo ago
comments(0)
5-min edit window · permanent after that